The Goldman Sachs Group Issues Pessimistic Forecast for Silence Therapeutics (NASDAQ:SLN) Stock Price

Silence Therapeutics (NASDAQ:SLN) had its price target decreased by The Goldman Sachs Group from $6.00 to $4.00 in a research note published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a sell rating on the stock.

Several other equities analysts have also recently weighed in on SLN. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Chardan Capital restated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Wednesday, January 29th. Finally, William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.67.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN opened at $4.74 on Tuesday. The stock has a market capitalization of $141.87 million, a price-to-earnings ratio of -3.02 and a beta of 1.08. The business has a 50-day moving average of $5.44 and a 200-day moving average of $11.48. Silence Therapeutics has a fifty-two week low of $4.06 and a fifty-two week high of $27.72.

Hedge Funds Weigh In On Silence Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SLN. Barclays PLC boosted its holdings in shares of Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after acquiring an additional 2,793 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Silence Therapeutics during the fourth quarter worth approximately $26,000. Y Intercept Hong Kong Ltd boosted its holdings in shares of Silence Therapeutics by 22.9% during the third quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock worth $383,000 after acquiring an additional 3,923 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after acquiring an additional 5,233 shares during the period. Finally, Virtus ETF Advisers LLC boosted its holdings in shares of Silence Therapeutics by 130.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after acquiring an additional 6,098 shares during the period. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.